NCT05455320 2026-01-16MonumenTAL-3Janssen Research & Development, LLCPhase 3 Active not recruiting864 enrolled
NCT03734198 2025-11-26IDA53French Innovative Leukemia OrganisationPhase 2 Active not recruiting29 enrolled
NCT03836014 2024-12-06CONFIRMAssistance Publique - Hôpitaux de ParisPhase 3 Active not recruiting436 enrolled
NCT03989414 2024-11-29A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)CelgenePhase 1/2 Active not recruiting424 enrolled
NCT02773030 2024-06-25A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple MyelomaCelgenePhase 1/2 Active not recruiting466 enrolled